BioCryst Pharmaceuticals BCRX Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$721.81M-394% | $245.85M+1,806% | $12.9M+154% | $5.09M+15,791% | $32K+100% | ||
| $461K+17.0% | $394K+17.6% | $335K+1.8% | $329K-0.6% | $331K+7.1% | ||
| $16.03M-32.6% | $23.79M+27.9% | $18.6M-12.7% | $21.3M-0.3% | $21.37M+0.1% | ||
| $4.85M+841% | $515K-69.6% | $1.69M+218% | -$1.44M-265% | $870K-59.8% | ||
| -$60.4M-271% | $35.36M+43.9% | $24.58M-19.3% | $30.46M+193% | -$32.59M-260% | ||
| -$3.53M-282% | $1.94M-67.3% | $5.92M+3,799% | -$160K-221% | $132K+123% | ||
| -$749K— | —— | —— | —— | $0— | ||
| $600K— | —— | —— | —— | $0— | ||
| $474K-96.9% | $15.49M+91,041% | $17K-99.8% | $7.31M-47.8% | $13.99M+91.7% | ||
| -$61.79M-121% | $291.96M+601% | $41.62M+0.8% | $41.3M+250% | -$27.52M-428% | ||
| $403K-49.8% | $802K-40.3% | $1.34M+651% | $179K+25.2% | $143K-78.8% | ||
| $489.48M— | —— | —— | —— | $0— | ||
| $0-100% | $125.5M+114% | $58.63M+99.8% | $29.34M-39.8% | $48.76M+23.4% | ||
| $221.24M+352% | $49M-32.9% | $73M+24.5% | $58.65M-22.8% | $76M+31.0% | ||
| —— | -$1.55M0.0% | -$1.55M0.0% | -$1.55M0.0% | -$1.55M— | ||
| -$268.65M-222% | -$83.49M-715% | $13.57M-53.4% | $29.13M+7.5% | $27.1M+52.2% | ||
| $400M— | —— | —— | —— | $0— | ||
| $19.48M+2,865% | $657K-75.2% | $2.65M-22.6% | $3.42M+43.1% | $2.39M— | ||
| $345K-18.6% | $424K-17.3% | $513K-4.3% | $536K+3.9% | $516K+44.9% | ||
| $1.19M-80.2% | $6M+856% | $628K-27.5% | $866K-35.9% | $1.35M-56.2% | ||
| $4.95M— | —— | —— | —— | $0— | ||
| $412.55M+289% | -$217.96M-271% | -$58.81M+20.2% | -$73.69M-14,029% | $529K+113% | ||
| -$72K— | —— | —— | $1.36M+201% | $451K+135% | ||
| $82.04M+958% | -$9.56M-134% | -$4.09M-115% | -$1.9M-440% | $558K— | ||
| $6.08M+543% | $946K-84.5% | $6.11M-18.8% | $7.53M-17.8% | $9.15M-9.7% | ||
| $1.43M— | —— | $992K-19.2% | $1.23M+122,600% | $1K-99.7% | ||
| $697.76M— | —— | —— | —— | $0— | ||
| $149K— | —— | —— | —— | $544K— | ||
| $600K— | —— | —— | —— | $0— | ||
| $251K+123% | -$1.09M-54.3% | -$707K+38.5% | -$1.15M+16.8% | -$1.38M+49.9% | ||
| $461K— | —— | —— | —— | $331K— | ||
| —— | $4.39M0.0% | $4.39M0.0% | $4.39M0.0% | $4.39M— | ||
| -$2.81M— | —— | —— | —— | $0— | ||
| —— | $891.5K0.0% | $891.5K0.0% | $891.5K0.0% | $891.5K— | ||
| -$3.53M-282% | $1.94M-67.3% | $5.92M+3,799% | -$160K-221% | $132K+123% | ||
| -$8.47M-164% | $13.19M-28.0% | $18.32M-64.4% | $51.47M+454% | -$14.55M-164% | ||
| $74K— | $0-100% | $30K-96.3% | $817K+291% | $209K— | ||
| $13.29M-0.2% | $13.32M+3.1% | $12.92M-3.6% | $13.4M-0.8% | $13.51M+0.1% | ||
| —— | $0— | $0— | $0— | $0— | ||
| —— | -$1.55M0.0% | -$1.55M0.0% | -$1.55M0.0% | -$1.55M— | ||
| $221.24M+352% | $49M-32.9% | $73M+24.5% | $58.65M-22.8% | $76M+31.0% | ||
| $345K-18.6% | $424K-17.3% | $513K-4.3% | $536K+3.9% | $516K+44.9% | ||
| —— | $3.88M0.0% | $3.88M0.0% | $3.88M0.0% | $3.88M— | ||
| $4.95M— | —— | —— | —— | $0— | ||
| $19.48M+2,865% | $657K-75.2% | $2.65M-22.6% | $3.42M+43.1% | $2.39M— | ||
| $33K— | —— | —— | —— | $6K— | ||
| $476K-92.7% | $6.48M-48.0% | $12.45M+215% | $3.96M— | $0— | ||
| $251.66M— | —— | —— | —— | $0— | ||
| $1.43M— | —— | —— | —— | $1K-99.8% | ||
| $3.17M— | —— | —— | $67K-75.7% | $276K-46.2% | ||
| -$62.19M-121% | $291.16M+623% | $40.28M-2.0% | $41.12M+249% | -$27.66M-370% | ||
| -$62.19M-121% | $291.16M+623% | $40.28M-2.0% | $41.12M+249% | -$27.66M-370% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does BioCryst Pharmaceuticals generate?
- BioCryst Pharmaceuticals (BCRX) generated $313.1M in operating cash flow over the trailing twelve months.
- What is BioCryst Pharmaceuticals's free cash flow?
- After $2.7M of capital expenditures, BioCryst Pharmaceuticals's free cash flow was $310.4M over the trailing twelve months, up 448.8% year over year.
- Where does BioCryst Pharmaceuticals's cash flow data come from?
- Every line is extracted from BioCryst Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
